8-K: Pulse Biosciences' nsPFA Shows Strong Thyroid Nodule Results

Pulse Biosciences announced the publication of positive First-In-Human clinical data for its CellFX nsPFA Percutaneous Electrode System in treating benign thyroid nodules, showing significant size reduction and no scarring.

Summary

• Early data from the First-In-Human clinical feasibility study of the CellFX nsPFA Percutaneous Electrode System for benign thyroid nodules has been published in the Journal Thyroid.
• The study, conducted by Professor Stefano Spiezia in Naples, Italy, demonstrated the effectiveness and safety of nsPFA energy.
• Fully treated nodules (Cohort 3) showed an average of 86% reduction in size at 1 year, with up to 93% reduction.
• Significant nodule size reduction of over 48% was observed as early as 2 weeks.
• No intranodular fibrosis or scarring was observed on follow-up ultrasounds.
• Patients experienced symptom relief.

Sentiment

Score: 8

Explanation: The announcement of positive First-In-Human clinical data, particularly the significant nodule reduction, rapid response, and favorable safety profile compared to existing treatments, indicates strong progress and potential for the CellFX nsPFA technology. The publication in a reputable journal further validates the findings. This is a very positive development for the company's pipeline.

Positives

• Achieved up to 93% reduction in benign thyroid nodule size at 1 year (average 86% reduction).
• Demonstrated rapid nodule size reduction, with over 48% reduction as early as 2 weeks.
• No intranodular fibrosis or scarring was observed on follow-up ultrasounds.
• Provided symptom relief for patients.
• The nonthermal mechanism of nsPFA preserves surrounding nerves and blood vessels, allowing for safe treatment in sensitive areas.
• Significantly faster rate of thyroid nodule volume reduction compared to Radiofrequency Ablation (RFA), achieving 71% reduction in one month versus RFA's typical six months for comparable shrinkage.
• Favorable safety profile.

Risks

• Actual results may differ materially from forward-looking statements due to known and unknown risks, uncertainties, and assumptions.
• Uncertainty regarding the effectiveness of the CellFX nsPFA Percutaneous Electrode System to safely and effectively treat benign thyroid nodules or cause significant nodule volume reductions.
• Uncertainty whether any clinical study will show that the novel nsPFA mechanism of action will deliver fast and precise ablations.
• Early clinical successes may not be predictive of the safety and effectiveness of any medical device.
• Uncertainty whether the CellFX nsPFA technology will become a disruptive, superior, and durable treatment option for benign thyroid nodules or any other medical condition, or otherwise advance current medical standards of care.

Future Outlook

Pulse Biosciences is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets, such as surgical soft tissue ablation, where it could have a profound positive impact on healthcare. The company believes its nsPFA technology has the potential to become a disruptive, superior, and durable treatment option for benign thyroid nodules and other medical conditions, advancing current medical standards of care.

Management Comments

• "We are very proud to have this data published in a leading scientific journal in the field, the renowned Journal Thyroid. The results of this study are extremely compelling and demonstrate nsPFAs ability to offer advantages in treating benign thyroid nodules compared to other methods such as thyroidectomy or thermal ablation. This technology provides a favorable safety profile, rapid symptom reduction, and lack of internodular fibrosis and scarring." Dr. Stefano Spiezia, Chief of Endocrine Surgery at Ospedale del Mare.
• "Unlike RFA, the nonthermal mechanism of nsPFA preserves surrounding nerves and blood vessels, allowing for safe and effective treatment of the entire nodule, even when located in sensitive areas like near the recurrent laryngeal nerve, esophagus, trachea, and critical arteries. Another key advantage of nsPFA over RFA is its significantly faster rate of thyroid nodule volume reduction: nsPFA achieved a 71% reduction within just one month, whereas RFA-treated nodules in four large clinical trials typically required six months to reach comparable shrinkage. The rapid reduction in nodule size combined with the absence of adverse effects supports the feasibility of this new approach and its potential to improve patient outcomes." Dr. Ralph Tufano, Pulse Biosciences Scientific Advisory Board Chair, Head and Neck Surgery.

Industry Context

The publication of positive First-In-Human data for nsPFA in treating benign thyroid nodules positions Pulse Biosciences' technology as a potentially superior alternative to existing methods like thyroidectomy, thermal ablation, and Radiofrequency Ablation (RFA). The nonthermal mechanism and rapid volume reduction offer distinct advantages, particularly in preserving critical surrounding tissues and achieving faster patient outcomes, which could disrupt the current standard of care for thyroid nodule treatment.

Comparison to Industry Standards

• nsPFA's nonthermal mechanism preserves surrounding nerves and blood vessels, unlike RFA, allowing for safe treatment in sensitive areas such as near the recurrent laryngeal nerve, esophagus, trachea, and critical arteries.
• nsPFA achieved a 71% reduction in thyroid nodule volume within just one month, significantly faster than RFA-treated nodules, which typically required six months to reach comparable shrinkage in four large clinical trials.
• The technology offers advantages over other methods like thyroidectomy or thermal ablation due to its favorable safety profile, rapid symptom reduction, and lack of internodular fibrosis and scarring.

Stakeholder Impact

• Patients: Potential for improved quality of life through a safer, more effective, and faster treatment option for benign thyroid nodules, with reduced scarring and preservation of critical tissues.
• Healthcare Providers/Surgeons: A new tool that offers a favorable safety profile and consistent positive outcomes, potentially simplifying procedures and expanding treatment options for sensitive areas.
• Shareholders: Positive clinical data and publication in a leading journal could increase investor confidence and potentially lead to future market opportunities and revenue growth.

Next Steps

• Continue development of CellFX nsPFA technology for atrial fibrillation.
• Continue development of CellFX nsPFA technology for surgical soft tissue ablation.

Key Dates

Recommendation

The First-In-Human clinical data for Pulse Biosciences' CellFX nsPFA Percutaneous Electrode System for benign thyroid nodules is exceptionally strong. Achieving an average 86% nodule reduction at one year, with rapid initial reduction and no scarring, represents a significant advancement over current standards like RFA, which is slower and carries more risks to surrounding tissues. The nonthermal mechanism is a key differentiator, enabling safer treatment in sensitive areas. This positive clinical validation, published in a reputable journal, de-risks the technology for this indication and highlights its potential for broader applications (atrial fibrillation, soft tissue ablation). This news significantly enhances the company's long-term growth prospects and market position, making it a compelling 'strong buy' for investors looking for innovative medical device companies with validated technology.

Keywords

Pulse Biosciences, PLSE, CellFX, nsPFA, Nanosecond Pulsed Field Ablation, Thyroid Nodules, Benign Thyroid Nodules, Clinical Study, Medical Device, Ablation, Bioelectric Medicine, Thyroid, Percutaneous Electrode System